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Objectives: Lipids are linked to many pathological processes including hepatic steatosis and liver
malignancy. This study aimed to explore lipid metabolism in hepatitis C virus (HCV) and HCV-related
hepatocellular carcinoma (HCC).
Methods: Serum lipids were measured in normal, HCV and HCV-HCC patients. Whole-genome microar-
ray was performed to identify potential signature genes involved in lipid metabolism characterizing normal
vs. HCV vs. HCV-HCC conditions.
Results: Serum cholesterol was significantly reduced in HCV and HCV-HCC patients compared with
normal controls, whereas there was no difference in glucose and triglycerides. Microarray analysis
identified 224 probe sets with known functional roles in lipid metabolism (ANOVA, 1.5-fold, P  0.001).
Gene-mediated fatty acid (FA) de novo synthesis and uptake were upregulated in HCV and this upregu-
lation was further enhanced in HCC. Genes involved in FA oxidation were downregulated in both the HCV
and HCC groups. The abnormality of cholesterol metabolism in HCV was associated with downregulation
of genes involved in cholesterol biosynthesis, absorption and transportation and bile acid synthesis; this
abnormality was further intensified in HCC.
Conclusions: Our data support the notion that HCV-related lipid metabolic abnormalities may contrib-
ute to hepatic steatosis and the development of cancer. Identification of these aberrations would stratify
patients and improve treatment algorithms.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide. The American Cancer Society report of
the incidence and prevalence of cancers within the USA states that
HCC continues to show the single greatest increase in incidence
compared with other cancers.1 Hepatocellular carcinoma is
unique in that it most often occurs against a background of
chronic liver disease and cirrhosis. Of the many risk factors for
HCC, hepatitis C virus (HCV) infection has been recognized as an
important cause of its rising incidence.2 Progress in the manage-
ment of HCC is dependent on our ability to: (i) identify the
highest-risk patients (those who will develop cancer) from the
larger cohort of HCV patients so that treatment can be initiated
early; (ii) understand the process of cancer initiation in the
highest-risk patients, and (iii) develop a therapeutic strategy based
on the key targets involved in tumour development.
It has been shown that hepatic steatosis, which is characterized
by the accumulation of fat in the liver, is a common
histological phenotype of a direct toxic effect of HCV on the
hepatocyte.3 According to previous reports, the prevalence of
hepatocellular steatosis in liver biopsy specimens from patients
This paper was presented at the American Hepato-Pancreato-Biliary Asso-
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with chronic hepatitis C is around 41–73%.4 This figure is higher
than in patients with chronic hepatitis B (27–51%) and autoim-
mune hepatitis (16–19%). It is also more than twice as high as the
expected prevalence of steatosis in the general population, sug-
gesting that HCV infection may have a direct effect on hepatic
lipid metabolism. Two different forms of hepatic steatosis have
been reported in patients with chronic HCV infection. Patients
infected with non-genotype 3 HCV strains usually have the clas-
sical metabolic risk factors for hepatocellular steatosis. By con-
trast, in patients infected with HCV genotype 3, steatosis is
generally induced by the virus itself through a direct cytopathic
effect. Mixed forms of steatosis can also be seen in HCV genotype
3-infected patients with metabolic risk factors.
Although hepatic steatosis has been reported to be associated
with more severe fibrosis and with rapid progression of disease in
chronic HCV infection,5,6 the mechanism linking HCV and ste-
atosis and how steatosis is related to liver malignancy remain
unclear. Both in vitro and in vivo studies have demonstrated that
the expression of HCV core protein can induce hepatic steatosis in
cell culture as well as in transgenic mice.7,8 Hepatic steatosis was
reported to predispose to lipid peroxidation and produce excess
free radical activity with the potential risk of genomic mutations.9
Hyperplasia of hepatocytes has been described in ob/ob mice with
fatty liver disease, suggestive of malignant changes secondary to
hepatic steatosis.10 In addition, hepatic steatosis developed
without significant inflammation and contributed to carcinogen-
esis in transgenic mice that expressed HCV core protein. These
studies indicated that hepatic steatosis is linked to the progression
of chronic hepatitis C-associated HCC. Recently, hepatic steatosis
has been proposed as a risk factor for HCC in patients with
chronic HCV infection. Ohata et al. reported that steatosis repre-
sented an independent risk factor for HCC in patients with HCV
infection.11 Hepatic steatosis was found to be associated with
increased frequency of HCC in patients with HCV-related cirrho-
sis.12 Further support is provided by the finding that hepatic ste-
atosis was a useful predictor of postoperative recurrence of HCV-
related HCC.13 All of these pieces of evidence suggest that hepatic
steatosis plays a role in the process of hepatocarcinogenesis.
Lipid metabolism is known to be an important process involved
in hepatic steatosis. Our hypothesis upon initiating these studies
was that hepatic lipid composition is important in the aetiology
and pathogenesis of HCV-associated HCC. Patients with HCV-
related cirrhosis are high-risk subjects for the development of
HCC. Investigation of the lipid metabolism in liver tissues from
high-risk patients as well as HCC patients would add new insight
into HCC initiation and/or progression. The objective of this
study was to explore the abnormality of lipid metabolism in HCV
cirrhotic patients and HCV cirrhotic cancer patients. To this end,
serum lipids were measured and microarray-based gene expres-
sion analysis using the Human Genome HG U133 Plus 2.0 Array
GeneChip® from Affymetrix, Inc. (Santa Clara, CA, USA) was
performed to probe >47 000 transcripts derived from ~38 500
well-characterized human genes. Real-time quantitative poly-
merase chain reaction (RT-qPCR) was applied to further confirm
the expression of genes involved in fatty acid (FA) de novo syn-
thesis, FA uptake, oxidation, antioxidant pathways, triglyceride
(TG) synthesis and catalysis, and cholesterol metabolism.
Materials and methods
Patients and liver tissue samples
In order to exclude the artefactual effects of ischaemia on the gene
expression profile, all the liver tissue samples in our study were
processed at the start of surgery. The normal control specimens
were obtained from patients during surgery for liver metastasis of
colorectal cancer or haemangioma. All the normal specimens were
histologically normal. HCV cirrhotic samples and HCV cirrhotic
cancer samples were obtained from patients who underwent
either tumour resection or transplantation. Liver tissue was
divided into two parts. One part was subjected to routine histo-
pathological evaluation and the other was frozen immediately in
liquid nitrogen and maintained at -80 °C until total RNA extrac-
tion. The sera samples were collected from patients at Indiana
University Hospital between June 2001 and July 2007. Normal
control sera samples were collected from patients with non-liver
disease and no-cancer diagnosis. For sera from HCV cirrhotic and
HCV cirrhotic cancer patients, inclusion criteria required that
patients be older than 18 years, positive for anti-HCV and positive
for serum HCV-RNA. Patients with underlying liver disease from
any other aetiology (i.e. alcohol, hepatitis B) were excluded, as
were patients treated with antiviral or immunosuppressive agents
within 6 months of enrolment or patients treated with drugs
known to produce hepatic steatosis, including corticosteroids,
high-dose oestrogen, methotrexate and amiodarone, within 6
months of enrolment. All subjects reported no or low alcohol
intake, but 25 of the normal controls, 30 HCV subjects and 22
HCV-related cancer patients had diabetes. All tissue was obtained
through Indiana University Human Subjects Research Institu-
tional Review Board (IRB) approved tissue acquisition protocols.
IRB authorization was obtained to analyse and present these data.
Serum analysis
All serum samples were taken after a 6–8 h fast. Serum was sepa-
rated from the blood samples by centrifugation at 1500 g for
15 min at room temperature. All the samples were aliquoted into
siliconized microcentrifuge tubes (PGC Scientifics Corp., Freder-
ick, MD, USA) and frozen at -80 °C until analysis. Serum glucose,
TG and total cholesterol (TC) were determined by SYNCHRON®
System(s) (Bristol, PA, USA) according to the manufacturer’s pro-
tocol. Serum glucose and lipid evaluation statistical analyses were
performed by one-way anova using InStat software (GraphPad
Software, Inc., San Diego, CA, USA). P-values of <0.05 were con-
sidered statistically significant.
Microarray procedure
Gene expression profiles of human liver tissue from normal control
(n = 9), HCV-infected cirrhotic liver (n = 9) and HCV-associated
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HCC tumour core tissue (n = 10) were compared by microarray
analysis using the Affymetrix HG U133 Plus 2.0 Array GeneChip®,
which contained >47 000 transcripts and variants derived from
~38 500 well-characterized human genes. All the subjects included
for microarray reported no alcohol intake and did not have diabe-
tes. Total RNA from liver tissues was prepared using the RNeasy
Mini Kit (Qiagen, Inc., Valencia, CA, USA) according to standard
protocols provided by the manufacturer. The integrity of total RNA
was verified with an Agilent 2100 Bioanalyser using the RNA 6000
Nano LabChip Kit (Agilent Technologies, Inc.,Palo Alto,CA,USA).
Standard Affymetrix protocols (GeneChip® Expression Analysis
Technical Manual) were used to synthesize biotinylated cRNA,
starting with 5 mg total RNA from each tissue sample, using the
Affymetrix kits for cDNA synthesis, in vitro transcription and
sample clean-up.A subsample of 15 mg of fragmented, biotinylated
cRNA from each independent sample was mixed into 300 ml of
hybridization cocktail, of which 200 ml were used for each hybrid-
ization. Hybridization occurred over 17 h at 42 °C. Samples were
hybridized to the Affymetrix GeneChip® (HG U133 Plus 2.0 Array
GeneChip®). Washing and scanning of the GeneChips® were
carried out according to standard protocols.
Microarray data analysis and statistics
In this study the GeneSifter microarray data analysis system (VizX
Laboratories LLC, Seattle, WA, USA; http://www.genesifter.net)
was used to analyse data generated from one-way anova among
normal control, HCV and HCV-associated HCC tumour groups
(1.5-fold; P  0.001). This program identifies differentially
expressed genes and establishes the biological significance based on
Gene Ontology (GO) Consortium (http://www.Geneontology.
org)14 and Kyoto Encyclopaedia of Genes and Genomes (KEGG)
public pathway resource (http://www.genome.jp/kegg/). The bio-
logical process ontologies and KEGG pathway terms associated
with the differentially expressed genes were examined using a
Z-score report. The Z-score was derived by ‘subtracting the
expected number of genes in a GO term meeting the criterion from
the observed number of genes, and dividing by the standard devia-
tion of the observed number of genes under the hypergeometric
distribution’.15 A positive Z-score indicates that more genes than
expected fulfilled the criterion in a certain group or pathway;
therefore, that group or pathway is likely to be affected.15 The
parameters used to identify differentially expressed genes using
GeneSifter were: global median normalization; one-way anova;
quality = 1; threshold = 1.5, and log transformation. Correction for
multiple testing was then performed according to Benjamini and
Hochberg.16 A false discovery rate of 5% was used as a cut-off for
statistical significance.
Quantitative real-time PCR
Quantitative RT-PCR was performed to verify the differentially
expressed transcripts detected by microarray as previously
reported.17 Total RNA was prepared from 20 normal controls, 20
HCV-positive cirrhotic livers and 20 HCV-HCC tumour samples.
cDNA was generated from 2 mg of total RNA in 20 ml of total
volume using a high-capacity cDNA Reverse Transcriptase Kit
(Applied Biosystems, Inc., Foster City, CA, USA). Quantitative
PCR was performed using the TaqMan® Universal PCR Master
Mix (Applied Biosystems, Inc.). Gene-specific primers were either
purchased from Applied Biosystems, Inc. or were custom-
designed using UMapIt Microarray-to-TaqMan Assay Mapping
Tool software (Applied Biosystems, Inc.). The assay IDs are sum-
marized in Table 1. Results were normalized against Ct values of
18S rRNA (Hs99999901_s1). The 2-DDCt method was used for rela-
tive quantification analysis.
Results
Serum lipid, glucose and body mass index
To determine any potential link between serum lipid or glucose
levels and/or body mass index (BMI) on the subsequent lipid
microarray profiles, we evaluated lipid, glucose and related clinical
parameters in 112 patients with HCV-positive cirrhosis, 73
patients with HCV-associated cirrhosis and cancer and 103
normal controls (Table 2). No significant differences were found
in serum TGs and glucose, but significant changes in serum TC
(one-way anova, P = 0.0001) and BMI (one-way anova, P =
0.0196) were observed among the three groups. When compared
with control levels, TC levels were low and BMI was high in HCV
cohorts. A comparison within the patient groups showed that the
level of TC in HCV alone was significantly lower than that in
HCV-associated HCC, whereas the change in other parameters
was not obvious.
Biological ontological pathway analysis of
differentially expressed genes
In order to explore the aberrant lipid metabolism in HCV and
HCV-associated cancer, microarray assay was performed with
Table 1 The assay ID for the primers used in real-time polymerase
chain reaction validation
Gene Accession no. Probe ID Assay ID (Applied
Biosystems, Inc.)
FASN1 AI954041 212218_s_at AIHR15B
ACACA BE855983 212186_at AII00BJ
HADH BC000306 201035_s_at AIMRUT7
PPARA BC004162 223438_s_at AIN0S0F
MLYCD NM_012213 218869_at Hs00201955_m1
SOD1 NM_000454 200642_at Hs00916176_m1
CAT AY028632 211922_s_at Hs00156308_m1
CH25H NM_003956 206932_at Hs02379634_s1
HMGCS2 NM_005518 204607_at Hs00985427_m1(I)
LCAT NM_000229 204428_s_at Hs01068069_m1(I)
RXRA NM_002957 202449_s_at Hs01067640_m1
AKR1D1 NM_005989 207102_at Hs00975612_m1
ACADL NM_001608 206069_s_at Hs00155630_m1
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three groups of human liver tissue (normal control, HCV-positive
cirrhotic liver, and HCV-associated cirrhosis and HCC tumour).
Microarray data were analysed using anova multiple group test
with Benjamini–Hochberg FDR correction. Filtered for probe sets
with corrected anova P-values of 0.001 and fold changes of
1.5, 3989 genes were differentially expressed in control vs. HCV
vs. HCV-HCC groups. Gene Ontology analysis showed metabolic
process is one of the major categories (Z-score = 5.75) in biologi-
cal process ontology. In this study, lipid metabolism was targeted
for further investigation. The KEGG terms (http://www.
genome.ad.jp/kegg)18 revealed FA metabolism (Z-score = 13.68),
peroxisome proliferators-activated receptor (PPAR) signalling
pathway (Z-score = 12.75) and bile acid biosynthesis (Z-score =
10.35) were significantly altered.
Differential expression of genes associated with FA
metabolism
Fatty acids are important energy storage molecules and serve as:
(i) major constituents of all biological membrane lipids; (ii)
important substrates for energy metabolism, and (iii) generators
of mediators of signal transduction and transcription, and physi-
ological regulators. Hierarchical cluster analysis revealed there are
three clusters of FA metabolism-associated genes. As shown in
Fig. 1, genes in the top cluster (cluster 1) were characterized by a
strong increased expression in the HCV group, but slightly or no
change in the HCC tumour group compared with normal con-
trols. This cluster has three genes: prostaglandin-endoperoxide
synthase 2 (PTGS2)/cyclooxygenase 2 (COX2); stearoyl-CoA
desaturase 5 (SCD5), and g-glutamyltransferase 5 (GGT5). The
second cluster is characterized by a slight increase or no change in
HCV patients, with the highest levels found consistently in HCC
tumours. These genes are mainly related to de novo synthesis and
uptake of FA; they are: acyl-coA synthetase long-chain family
member 4 (ACSL4); acetoacetyl-CoA synthetase (AACS); elonga-
tion of very long-chain fatty acids-like 1 (ELOVL1); fatty acid
synthase (FASN); glyceronephosphate O-acyltransferase
(GNPAT); aldo-keto reductase family 1, member C3 (AKR1C3),
and acetyl-coenzyme A carboxylase a (ACACA). Genes in the
third cluster are distinguished by a gradual but large-magnitude
decline in transcript levels between the HCV group and the HCC
tumour group. This cluster includes genes involved in the catabo-
lism of FA, such as enzymes for oxidation, detoxification pathways
and oxidation regulation. Genes involved in the FA oxidation
pathway are: acyl-coenzyme A oxidase 1, palmitoyl (ACOX1);
acyl-coenzyme A oxidase 2, branched-chain (ACOX2); hydroxy-
acid oxidase 2 (HAO2); hydroxyacyl-coenzyme A dehydrogenase
(HADH); acyl-coenzyme A dehydrogenase, C-4 to C-12 straight-
chain (ACADM); acetyl-coenzyme A acyltransferase 1 (peroxiso-
mal 3-oxoacyl-coenzyme A thiolase) (ACAA1); enoyl coenzyme A
hydratase short-chain 1 mitochondrial (ECHS1); cytochrome
P450, family 4, subfamily A, polypeptide 11 (CYP4A11); acyl-
coenzyme A dehydrogenase, short/branched-chain (ACADSB);
Table 2 Serum lipid and glucose profiles for non-liver disease control, hepatitis C virus (HCV) cirrhotic and HCV hepatocellular carcinoma
(HCC) patients
Normal control HCV cirrhosis HCV-HCC
Sample, n 103 112 73
Body mass indexa,b 26.7359  0.476 28.577  0.475 27.55  0.51
Total cholesterol, mg/dlc 172.757  7.363 127.536  3.984 140.973  4.713
Triglycerides, mg/dl 144.97  11.564 150.094  19.082 142.958  13.197
Glucose, mg/dl 117.757  6.376 121.598  5.258 133.56  8.545
aResults are mean  standard error of the mean
bP = 0.0196 (one-way ANOVA); cP = 0.0001 (one-way ANOVA)
NL HCV HCV-HCC
I
II
III
-2 +20
Figure 1 Hierarchical cluster analysis of fatty acid (FA) metabolism
comparing gene expression among non-liver disease normal control
(NL), hepatitis C virus (HCV)-related cirrhotic liver and HCV hepato-
cellular carcinoma (HCC) tumour samples
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acyl-coenzyme A dehydrogenase, C-2 to C-3 short-chain
(ACADS); acyl-coenzyme A dehydrogenase, long-chain
(ACADL), and cytochrome P450, family 2, subfamily J, polypep-
tide 2 (CYP2J2). Genes involved in FA oxidation regulation
include: peroxisome proliferator-activated receptor a (PPARA);
acetyl-coenzyme A carboxylase b (ACACB); peroxisome
proliferator-activated receptor g coactivator 1 a (PPARGC1A);
malonyl-CoA decarboxylase (MLYCD); solute carrier family 25
(carnitine/acylcarnitine translocase), member 20 (SLC25A20);
protein kinase, AMP-activated, g 2 non-catalytic subunit
(PRKAG2); apolipoprotein A-V (APOA5), and carnitine acetyl-
transferase (CRAT). Genes responsible for the detoxification
pathways include glycine-N-acyltransferase (GLYAT). Table 3
summarizes the differentially expressed genes associated with FA
metabolism in normal control vs. HCV vs. HCV-HCC. The dif-
ferentially expressed genes in FA metabolism suggest that FA de
novo synthesis and uptake are very active in the progression of
HCC, whereas the oxidation and degradation of FA are impaired.
Differential expression of genes associated
with TG metabolism
Triglycerides are extremely efficient molecules for energy storage
derived from the esterification of free FA. These molecules have
been shown to be significantly involved in metabolic energy pro-
vision and lipoprotein metabolism. As Fig. 2 shows, the transcript
level of TGs metabolism-related genes was characterized by a
gradual decline in the HCV group and a substantial decline in the
HCC group. Table 4 summarizes the differential expressed genes
involved in TG metabolism in normal control vs. HCV vs. HCV-
HCC. Together, the downregulation of microsomal TG transfer
protein (MTTP), diacylglycerol O-acyltransferase homologue 2
(mouse) (DGAT2), apolipoprotein A-V (APOA5), lipase, hepatic
(LIPC) and cholesteryl ester transfer protein plasma (CETP)
resulted in the reduced export of lipids from liver as well as the
accumulation of TGs in hepatocytes, which may cause severe lipo-
toxicity for liver.
Differential expression of genes associated with
cholesterol metabolism and bile acid synthesis
Our study identified that genes participated in cholesterol
metabolism could be divided into two groups (Fig. 3). The first
group includes cholesterol 25-hydroxylase (CH25H) and very low
density lipoprotein receptor (VLDLR), which were upregulated in
the HCV group, but showed no change or increase in HCC
tumour compared with control. Genes in the second group are
characterized by downregulation in HCV patients and a subse-
quent strong repression in HCC patients. Levels of expression of
cholesterol metabolism related genes are summarized in Table 5.
Together, the cholesterol biosynthesis is inhibited by the up-
regulation of the negative regulator CH25H, as well as the
downregulation of cholesterol biosynthesis enzyme 3-hydroxy-
3-methylglutaryl-coenzyme A synthase 2 (mitochondrial)
(HMGCS2). The absorbing and transportation of cholesterol are
also decreased by downregulation of apolipoprotein A-I
(APOA1), apolipoprotein F (APOF), CETP, lecithin-cholesterol
acyltransferase (LCAT) (Niemann–Pick disease, type C1, gene)-
like 1 (NPC1L1) and sortilin-related receptor, L (DLR class) A
repeats-containing (SORL1). Unexpectedly, VLDLR was increased
by 4.2-fold and 3.5-fold in HCV and HCV-HCC patients, respec-
tively, compared with normal controls. Genes participating in the
regulation of cholesterol metabolism were also altered. Superoxide
dismutase 1 (SOD1), which is responsible for destroying free
superoxide radicals, was significantly decreased in the HCV and
HCV-HCC patient groups compared with the normal controls.
Bile acid synthesis genes, including cytochrome P450, family 39,
subfamily A, polypeptide 1 (CYP39A1), and aldo-keto reductase
family 1, member D1 (d 4-3-ketosteroid-5-b-reductase)
(AKR1D1), were downregulated.
Validation of microarray data by qPCR
Twelve transcripts (FASN [AI954041), ACACA [BE855983],
MLYCD [NM_012213], PPARA [BC004162], SOD1
[NM_000454], CAT [AY028632], HADH [BC000306], CH25H
[NM_003956], HMGCS2 [NM_005518] RXRA [NM_002957],
LCAT [NM_000229], AKR1D1 [NM_005989]), each from normal
control, HCV cirrhotic liver and HCV cirrhotic HCC tumour,
were selected for validating the microarray data using qPCR. A
high degree of correlation between the microarray data and the
data from qRT-PCR was observed (R2 = 0.8202, slope = 1.359, n =
22) (Fig. 4).
Discussion
The results from this study indicate the following regarding HCV
and HCV-HCC:
1 increased de novo synthesis and uptake of FA and impaired FA
oxidation are associated with the pathophysiology of HCV
infection;
2 increased TG synthesis results from enhanced de novo lipogen-
esis and accumulated TG storage results from reducing lipid
export from liver, which may cause severe lipotoxicity for liver;
3 cholesterol metabolism is decreased by downregulation of the
genes involved in cholesterol synthesis, absorption and trans-
port and bile acid synthesis is inhibited by the reduced expres-
sion of CYP39A1 and AKR1D1, and
4 antioxidant pathways including SOD and catalase (CAT) are
also decreased and thereby fail to neutralize reactive oxygen
species (ROS) produced from mitochondrial, peroxisomal and
microsomal oxidation.
These transcriptional changes are associated with increased
levels of hepatic lipid and decreased levels of cholesterol. To our
knowledge, this is one of the few studies to investigate the molecu-
lar causes of the abnormal lipid metabolism in human hepatitis
C-related cirrhosis and hepatitis C-associated cancer by using
whole-genome microarrays. Our data suggest that aberrant FA de
novo synthesis and impaired degradation of lipid contribute to the
HPB 629
HPB 2010, 12, 625–636 © 2010 International Hepato-Pancreato-Biliary Association
Table 3 Differential expression of fatty acid metabolism-related genes
Accession no. Probe ID Gene symbol Gene name Fold change
HCV HCV-HCC
Fatty acid biosynthesis
NM_000963 204748_at PTGS2 Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
3.14 –
AL571375 224901_at SCD5 Stearoyl-CoA desaturase 5 4.32 –
NM_022977 202422_s_at ACSL4 Acyl-CoA synthetase long-chain family member 4 9.19 15.42
NM_023928 218434_s_at AACS Acetoacetyl-CoA synthetase 2.29 3.44
H93026 57163_at ELOVL1 Elongation of very long-chain fatty acids
(FEN1/Elo2, SUR4/Elo3, yeast)-like 1
1.81 2.29
AB018580 209160_at AKR1C3 Aldo-keto reductase family 1, member C3
(3-a hydroxysteroid dehydrogenase, type II)
– 2.79
BC003005 200627_at PTGES3 Prostaglandin E synthase 3 (cytosolic) – 1.60
NM_014236 201956_s_at GNPAT Glyceronephosphate O-acyltransferase – 1.98
AI954041 212218_s_at FASN Fatty acid synthase – 2.70
BE855983 212186_at ACACA Acetyl-coenzyme A carboxylase a – 1.97
Fatty acid oxidation
T62985 213501_at ACOX1 Acyl-coenzyme A oxidase 1, palmitoyl -1.92 -2.20
BF435852 227962_at ACOX1 Acyl-coenzyme A oxidase 1, palmitoyl -2.01 -3.80
NM_003500 205364_at ACOX2 Acyl-coenzyme A oxidase 2, branched-chain -2.64 -3.92
R06750 238160_at ACOT12 Acyl-coA thioesterase 12 -1.57 -8.14
AI860341 214274_s_at ACAA1 Acetyl-coenzyme A acyltransferase 1
(peroxisomal 3-oxoacyl-coenzyme A thiolase)
-1.83 -4.30
NM_001607 202025_x_at ACAA1 Acetyl-coenzyme A acyltransferase 1
(peroxisomal 3-oxoacyl-coenzyme A thiolase)
-2.32 -5.51
NM_000017 202366_at ACADS Acyl-coenzyme A dehydrogenase, C-2 to C-3
short-chain (ACADS)
-2.60 -3.29
NM_001609 205355_at ACADSB Acyl-coenzyme A dehydrogenase,
short/branched-chain (ACADSB)
-3.44 -6.46
BE897866 226030_at ACADSB Acyl-coenzyme A dehydrogenase,
short/branched-chain (ACADSB)
-4.03 -6.28
NM_000016 202502_at ACADM Acyl-coenzyme A dehydrogenase, C-4 to C-12
straight-chain
-1.86 -2.52
NM_001608 206069_s_at ACADL Acyl-coenzyme A dehydrogenase, long-chain -3.16 -7.42
D16350 210377_at ACSM3 Acyl-coA synthetase medium-chain family
member 3
-5.48 -19.19
NM_005622 205942_s_at ACSM3 Acyl-coA synthetase medium-chain family
member 3
-6.55 -27.51
NM_001995 207275_s_at ACSL1 Acyl-coA synthetase long-chain family member 1 -1.72 -3.13
AF237813 209460_at ABAT 4-aminobutyrate aminotransferase -1.77 -3.12
NM_000663 206527_at ABAT 4-aminobutyrate aminotransferase -3.12 -3.91
NM_001701 206913_at BAAT Bile acid coenzyme A:
amino acid N-acyltransferase
(glycine N-choloyltransferase)
-2.12 -2.74
NM_020139 218285_s_at BDH2 3-hydroxybutyrate dehydrogenase, type 2 – -2.62
AW136198 235155_at BDH2 3-hydroxybutyrate dehydrogenase, type 2 -1.71 -4.56
NM_015974 220753_s_at CRYL1 Crystallin, lambda 1 -1.90 -2.38
NM_017545 220224_at HAO1 Hydroxyacid oxidase (glycolate oxidase) 1(HAO1) -1.82 -4.82
NM_016527 220801_s_at HAO2 Hydroxyacid oxidase 2 (long-chain) -5.99 -18.55
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Table 3 Continued
Accession no. Probe ID Gene symbol Gene name Fold change
HCV HCV-HCC
AF001903 211569_s_at HADH Hydroxyacyl-coenzyme A dehydrogenase -1.78 -2.43
NM_005327 201036_s_at HADH Hydroxyacyl-coenzyme A dehydrogenase -1.74 -2.13
BC000306 201035_s_at HADH Hydroxyacyl-coenzyme A dehydrogenase -2.13 -2.63
BC001627 223211_at HACL1 2-hydroxyacyl-CoA lyase 1 -1.70 -2.07
D26480 210452_x_at CYP4F2 Cytochrome P450, family 4, subfamily F,
polypeptide 2
-1.55 -3.84
D12620 206514_s_at CYP4F3 Cytochrome P450, family 4, subfamily F,
polypeptide 3
-1.63 -4.68
BC041158 1554837_a_at CYP4A11 Cytochrome P450, family 4, subfamily A,
polypeptide 11
-3.80 -7.93
NM_000778 207407_x_at CYP4A11 Cytochrome P450, family 4, subfamily A,
polypeptide 11
-2.49 -4.86
D13705 211231_x_at CYP4A11 Cytochrome P450, family 4, subfamily A,
polypeptide 11
-4.02 -9.37
NM_000775 205073_at CYP2J2 Cytochrome P450, family 2, subfamily J,
polypeptide 2
-2.08 -6.89
NM_000236 206606_at LIPC Lipase, hepatic -5.07 -10.47
NM_004092 201135_at ECHS1 Enoyl coenzyme A hydratase, short-chain, 1,
mitochondrial
-1.50 -1.78
NM_018281 218552_at ECHDC2 Enoyl coenzyme A hydratase domain
containing 2
-1.93 -3.31
AF233336 209368_at EPHX2 Epoxide hydrolase 2, cytoplasmic -2.88 -8.36
NM_012254 219733_s_at SLC27A5 Solute carrier family 27 (fatty acid
transporter), member 5
-2.71 -9.21
Fatty acid oxidation regulation
AF202889 224243_at APOA5 Apolipoprotein A-V -2.78 -8.39
AF202890 224244_s_at APOA5 Apolipoprotein A-V -2.95 -11.06
R99037 214584_x_at ACACB Acetyl-coenzyme A carboxylase b -2.23 -2.84
NM_000755 205843_x_at CRAT Carnitine acetyltransferase -1.66 -1.53
NM_012213 218869_at MLYCD Malonyl-CoA decarboxylase -1.72 -3.28
BC004162 223438_s_at PPARA Peroxisome proliferator-activated receptor a -2.04 -3.60
NM_013261 219195_at PPARGC1A Peroxisome proliferator-activated receptor g,
coactivator 1 a
-1.93 -6.53
AF087875 222582_at PRKAG2 Protein kinase, AMP-activated, g 2
non-catalytic subunit
-2.13 -3.10
NM_016203 218292_s_at PRKAG2 Protein kinase, AMP-activated, g 2
non-catalytic subunit
-1.92 -2.99
AJ249976 233748_x_at PRKAG2 Protein kinase, AMP-activated, g 2
non-catalytic subunit
-1.70 -2.75
BC001689 203658_at SLC25A20 Solute carrier family 25 (carnitine/
acylcarnitine translocase), member 20
-1.72 -2.79
Detoxification and antioxidation pathway
NM_004121 205582_s_at GGT5 g-glutamyltransferase 5 2.18 -
NM_005838 206930_at GLYAT Glycine-N-acyltransferase -4.84 -13.25
AI793201 231683_at GLYAT Glycine-N-acyltransferase -4.87 -14.21
AW024233 222083_at GLYAT Glycine-N-acyltransferase -4.02 -20.22
AY028632 211922_s_at CAT Catalase -2.56 -3.94
HCV, hepatitis C virus; HCC, hepatocellular carcinoma
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development of HCV-related steatosis, and the abnormal lipid
and cholesterol metabolism involved in the pathophysiology of
HCV may also contribute to hepatocarcinogensis.
Hepatitis C virus infection has been shown to interfere with
lipid metabolism by increasing FA neosynthesis, impairing FA
oxidation, increasing TG accumulation, and decreasing choles-
terol metabolism activity.19–23 In the current study, we demon-
strate that enhanced de novo FA synthesis in HCV cirrhotic
patients is congruent with an upregulation of AACS, ACSL4,
ELOVL1 and PRGES3, and this process is further enhanced with
the additional elevated expression of FASN and ACACA in HCV
cirrhotic HCC patients. The expression of FASN is extremely low
in normal cells and tissues, whereas it is significantly upregulated
or activated in many cancer types. For example, extremely high
levels of FASN are expressed in premalignant, invasive and meta-
static lesions of many human epithelial cancers.24–27 Because the
over-expression or increased activity of FASN represents one of
the most frequent phenotypic alterations in cancer cells, FASN
may actively contribute to the development, maintenance and/or
promotion of the malignant phenotype. Consistent with the
reported data, our study found FASN expression was significantly
increased by more than two-fold in HCV-HCC tumour patients
compared with normal controls. Interestingly, FASN has also been
shown to be an HCV-inducible gene which directly links viral
infection to the lipid metabolic disorder.28 However, the expres-
sion of FASN in HCV-positive cirrhotic patients did not show any
significant change in this study. Most genetic alterations over-
lapped between the HCV and HCV-HCC groups compared with
normal tissue and far fewer differences were observed between the
two diseased groups. The differential expression of FASN in HCV
and HCV-HCC patients highlights a potential to identify hepatitis
C patients at highest risk for cancer. FASN is more likely to func-
tion as a metabolic intermediate of oncogenesis linking energy,
anabolism and malignant transformation in HCV-associated
cancer development.
ACACA is an enzyme involved in the initial phase of TG and FA
synthesis and the rate-limiting enzyme for the long-chain FA syn-
thesis that catalyses the ATP-dependent carboxylation of acetyl-
CoA to malonyl-CoA (also a FASN substrate). ACACA has been
shown to be over-expressed at both the mRNA and protein levels,
not only in advanced breast carcinomas, but also in preneoplastic
lesions associated with increased risk for the development of infil-
trating breast cancer.29 Knockdown of ACACA by RNAi impaired
tumour cell proliferation and caused cell death.30,31 Here, we
showed that the expression of ACACA did not change in HCV
cirrhotic cohorts compared with normal controls, which is con-
sistent with a previous report from Yasui et al.32 However, it dis-
played a 1.97-fold increase in HCC tumour samples. Further
investigation about whether ACACA is a predictor of HCC in
patients with HCV-related cirrhosis and how ACACA functions in
HCV-associated HCC initiation or progression will add insight
into the malignancy mechanism of HCV-associated hepatic ste-
atosis. Sterol regulatory element-binding protein-1 (SREBP-1) has
been described as a transcription factor that is selectively involved
in the activation of genes associated with FA metabolism and de
novo lipogenesis. Unexpectedly, the expression of SREBP-1 was
not significantly changed in either HCV cirrhotic or HCV-HCC
patients.
Fatty acid oxidation occurs in three subcellular organelles, with
b-oxidation confined to mitochondria and peroxisomes and
CYP4A-catalysed w-oxidation occurring in the endoplasmic
reticulum.33 In this study, we found genes involved in FA
b-oxidation were downregulated: the expression of PPARA,
HADH and ACOX1 was substantially inhibited in both HCV cir-
rhotic and HCC patients. Carnitine palmitoyl transferase-1 (CPT-
1), the rate-limiting enzyme of mitochondrial b-oxidation, is the
main catabolic pathway of FA and of the acyl CoA oxidase (AOX).
Interestingly, we did not observe the differential expression of
CPT-1 among these three groups of samples. Obviously, the
decreased expression of PPARA, ACADS, ACADL, HADHA and
ACOX1 may lead to steatosis in HCV cirrhotic patients through
downregulation of the b-oxidation of FA. We also noticed that
genes involved in antioxidation and detoxification were down-
regulated. The decreased expression of GLYAT, GGT5 and CAT
indicates a failure of neutralizing ROS produced from FA oxida-
tion and a reduction in hepatoprotection. The impaired FA oxi-
dation is most likely exacerbated in HCV-associated cancer
patients in response to an amplified expression of those genes.
Therefore, HCV infection resulted in an impairment of fat
homeostasis, insufficient FA oxidation and excess ROS. This det-
rimental alteration may also contribute to the initiation and pro-
gression of HCC.
Triglycerides are efficient molecules for energy storage and play
a fundamental role in several different aspects of lipid metabolism
and energy supply. Previous studies reporting serum/plasma TG
levels in HCC patients have been inconsistent, ranging from
NL HCV HCV-HCC
-2 +20
Figure 2 Hierarchical cluster analysis of triglycerol metabolism com-
paring gene expression among non-liver disease normal control
(NL), hepatitis C virus (HCV)-related cirrhotic liver and HCV hepato-
cellular carcinoma (HCC) tumour samples
632 HPB
HPB 2010, 12, 625–636 © 2010 International Hepato-Pancreato-Biliary Association
decreased to increased to no significant change.34–36 In our study,
FA de novo synthesis was extremely increased and FA oxidation
was substantially inhibited. Genes involved in lipid export from
liver such as MTTP, DGAT2, APOA5 and CETP, were significantly
downregulated. However, serum lipid profile analysis showed that
the level of serum TGs did not show any significant change in
either HCV cirrhotic or HCV cirrhotic cancer patients compared
with controls. This may have resulted from the induced lipogen-
esis and impaired TGs secretion by HCV core protein.37 Serum
TGs level may not be a reliable marker for reflecting the serum
lipid profile of HCV and HCV-associated cancer patients.
Cholesterol is not only an essential molecule for building cell
membranes, but also the precursor to several essential hormones,
bile acids and oxysterols. In HCC and chronic liver diseases, the
synthesis and metabolism of cholesterol are impaired.34,35,38 In our
study in HCV cirrhotic and HCV cirrhotic HCC patients, we
found that both groups displayed lower serum cholesterol levels
than the normal controls, but the cholesterol level in cancer
patients showed a slighter increase than that in HCV cirrhotic
non-cancer cohorts. Consistently, our microarray analysis identi-
fied that cholesterol 25-hydroxylase (CH25H), which is an impor-
tant negative regulator for cholesterol synthesis, was significantly
upregulated in HCV cirrhotic samples, but did not show signifi-
cant change in HCC. No difference was observed in the gene
expression of hepatic 3-hydroxy-3-methyl-glutaryl-CoA reduc-
tase (HMGR), the rate-limiting step in cholesterol biosynthesis,
cholesterol 7-hydroxylase (CYP7A1), the rate-limiting enzyme in
the synthesis of bile acid from cholesterol, liver X receptors
(LXRs), or maintenance of cholesterol homeostasis through
regulating Cyp7A1 and ATP-binding cassette transporter-A1
(ABCA1). SREBP-2, which is best known for the upregulation of
genes involved in cholesterol biosynthesis and uptake, did not
display any significant change in patient groups compared with
controls. Quantitative RT-PCR confirmed the non-differential
expression of these genes (data not shown). Low-density lipopro-
tein receptor (LDLR), which plays a critical role in regulating the
amount of cholesterol in the blood, was also not detected in our
list (anova, P < 0.001). However, we found downregulation of
LDLR in both HCV and HCV-HCC with a P-value > 0.001 but
<0.05. Interestingly, the expression of VLDLR increased by 4.2-
fold and 3.5-fold in HCV cirrhotic and HCV-HCC patients,
respectively. One possible explanation is that the enhanced
expression of VLDR compensates for the increased accumulation
of lipids in the liver. Saitoa et al. demonstrated that the ablation of
cholesterol biosynthesis in neural stem cells increases their
expression of vascular endothelial growth factor (VEGF) and
angiogenesis but causes neuron apoptosis.39 Whether the
impaired endogenous cholesterol biosynthesis is related to
hepatic angiogenesis and/or hepatocyte regeneration requires
further investigation.
Table 4 Differential expression of triglyceride metabolism-related genes
Accession no. Probe ID Gene symbol Gene name Fold change
HCV HCV-HCC
AI623321 205675_at MTTP Microsomal triglyceride transfer protein -1.50 -4.20
AF097831 217289_s_at – Glucose-6-phosphatase, catalytic subunit -2.48 -3.42
AW469523 226064_s_at DGAT2 Diacylglycerol O-acyltransferase homologue 2 (mouse) -4.30 -3.57
AB048286 224327_s_at DGAT2 Diacylglycerol O-acyltransferase homologue 2 (mouse) -3.90 -4.38
AF202889 224243_at APOA5 Apolipoprotein A-V -2.78 -8.39
AF202890 224244_s_at APOA5 Apolipoprotein A-V -8.39 -11.06
NM_000236 206606_at LIPC Lipase, hepatic -5.07 -10.56
NM_000078 206210_s_at CETP Cholesteryl ester transfer protein, plasma -2.81 -24.15
HCV, hepatitis C virus; HCC, hepatocellular carcinoma
NL HCV HCV-HCC
-2 +20
Figure 3 Hierarchical cluster analysis of cholesterol and bile acid
metabolism comparing gene expression among non-liver disease
normal control (NL), hepatitis C virus (HCV)-related cirrhotic liver and
HCV hepatocellular carcinoma (HCC) tumour samples
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Table 5 Differential expression of cholesterol and bile acid metabolism-related genes
Accession no. Probe ID Gene
symbol
Gene name Fold change
HCV HCV-HCC
Cholesterol biosynthesis
NM_005518 204607_at HMGCS2 3-hydroxy-3-methylglutaryl-coenzyme A synthase 2
(mitochondrial)
-1.98 -2.32
N58493 213789_at EBP Emopamil binding protein (sterol isomerase) -2.34 -1.89
Cholesterol transport, absorption
L22431 209822_s_at VLDLR Very low density lipoprotein receptor 4.25 3.56
X02162 217073_x_at APOA1 Apolipoprotein A-I – -1.74
NM_000039 204450_x_at APOA1 Apolipoprotein A-I -1.50 -1.77
AF123759 219340_s_at CLN8 Ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive
with mental retardation)
-1.50 -2.15
AF123758 223912_s_at CLN8 Ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive
with mental retardation)
-1.50 -2.23
AF123757 222874_s_at CLN8 Ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive
with mental retardation)
– -3.16
W93695 229958_at CLN8 Ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive
with mental retardation)
-1.83 -3.52
NM_001638 207262_at APOF Apolipoprotein F -17.20 -2.90
NM_000229 204428_s_at LCAT Lecithin-cholesterol acyltransferase -3.44 -13.50
NM_000078 206210_s_at CETP Cholesteryl ester transfer protein, plasma -2.81 -23.97
AF192523 224305_s_at NPC1L1 NPC1 (Niemann–Pick disease, type C1, gene)-like 1 -1.98 -2.26
NM_003105 203509_at SORL1 Sortilin-related receptor, L(DLR class) A
repeats-containing
-1.96 -4.43
AV728268 212560_at SORL1 Sortilin-related receptor, L(DLR class) A
repeats-containing
-2.11 -4.68
Cholesterol metabolism regulation
NM_003956 206932_at CH25H Cholesterol 25-hydroxylase 8.72 –
NM_006556 203515_s_at PMVK Phosphomevalonate kinase -1.73
NM_002957 202449_s_at RXRA Retinoid X receptor, a -2.06 -2.39
BE675800 202426_s_at RXRA Retinoid X receptor, a -3.44 -2.46
AJ249976 233748_x_at PRKAG2 Protein kinase, AMP-activated, g 2 non-catalytic
subunit
-1.70 -2.75
NM_016203 218292_s_at PRKAG2 Protein kinase, AMP-activated, g 2 non-catalytic
subunit
-1.92 -2.99
AF087875 222582_at PRKAG2 Protein kinase, AMP-activated, g 2 non-catalytic
subunit
-2.13 -3.10
BF063728 227731_at CNBP CCHC-type zinc finger, nucleic acid binding protein -1.21 -1.47
Bile acid biosynthesis
AI796334 244407_at CYP39A1 Cytochrome P450, family 39, subfamily A, polypeptide
1
-4.01 -6.21
NM_016593 220432_s_at CYP39A1 Cytochrome P450, family 39, subfamily A, polypeptide
1
-3.17 -17.16
BC010358 1553977_a_at CYP39A1 Cytochrome P450, family 39, subfamily A, polypeptide
1
-3.55 -16.25
NM_005989 207102_at AKR1D1 Aldo-keto reductase family 1, member D1
(d 4-3-ketosteroid-5-b-reductase)
-4.69 -15.56
Antioxidant pathways
NM_000454 200642_at SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral
sclerosis 1 (adult))
-1.50 -1.85
HCV, hepatitis C virus; HCC, hepatocellular carcinoma
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Conclusions
Although a small number of samples were used in this study, our
data warrant further investigation into HCV-related lipid meta-
bolic abnormalities. Our results support the notion that HCV-
related lipid metabolic abnormalities may contribute to hepatic
steatosis and the development of cancer. The identification of
these aberrations would stratify patients and improve treatment
algorithms.
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